AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01081769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate injection
Description: injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
Study NCT01081769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral antipsychotics
Description: daily treatment according to local label for maximally 24 months
Study NCT02059655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Study NCT02059655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eye drop solution
Description: Artificial tear drops
Study NCT03722251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing
Study NCT04013815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block with ropivacaine
Description: The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
Study NCT04013815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block with ropivacaine
Description: The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
Study NCT03881735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT03881735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enasidenib
Description: Given PO
Study NCT03881735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study NCT02438618 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery for Ponto bone anchored hearing aids
Study NCT02438618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for Ponto bone anchored hearing aids
Study NCT03671096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrastromal TCA Inlay
Description: An intrastromal inlay that will be provided to correct the required hyperopic correction
Study NCT04386096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software with medication continuity tools
Description: Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
Study NCT04386096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mehealth for ADHD software with no medication continuity tools
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.
Study NCT02836418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study NCT04522518 — intervention group
Intervention type: DEVICE
Intervention: PmP-C App
Description: The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to.
Study NCT01260350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily
Study NCT03964545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
Study NCT03800745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colace 100Mg Capsule
Description: Prescribed to Arm B
Study NCT02518048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 Aerosol foam
Study NCT03800745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax
Description: Prescribed to Arm C
Study NCT02518048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betesil® 2.25 mg
Study NCT02858583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CC+SI
Description: chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
Study NCT02858583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3:1 C:V
Description: During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
Study NCT03347305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated DP
Description: Energy expenditure measurement
Study NCT03347305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorimetric chamber
Description: The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
Study NCT02148796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncho-Vaxom (BV)
Description: Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package
Study NCT02148796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule will be used that will be indistinguishable from the active study drug.
Study NCT00408642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support
Description: The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
Study NCT00408642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard adherence support
Description: The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
Study NCT06578442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Field Treatment
Description: Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.
Study NCT06578442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation Coping Training
Description: The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation.
Study NCT00777270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of episiotomy or second degree tears
Description: continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
Study NCT00777270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of episiotomy or second degree tears
Description: interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
Study NCT03525275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
Study NCT03525275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-surgical shoulder protocol
Description: Surgery specific post-surgical physical therapy protocol
Study NCT03525275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-surgical shoulder protocol
Description: Surgery specific post-surgical physical therapy protocol
Study NCT02941211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueduct -100
Study NCT02757833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.
Description: Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
Study NCT04039568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
Study NCT04039568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi Meditation (SSM)
Description: This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
Study NCT01636193 — intervention group
Intervention type: BIOLOGICAL
Intervention: Oral Rotarix®
Description: 2 doses administered orally.
Study NCT01636193 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
Study NCT01082705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
Study NCT01082705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
Study NCT03612596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative visualization
Description: Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
Study NCT03612596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard self-regulation
Description: Participants self-monitor steps using a wearable device, app, and a hand-written step log
Study NCT01805518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Scelectium Tortuosum
Description: One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d.
Study NCT00531115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab 5mg/ml
Description: Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment.
Study NCT02024074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sestamibi (Tc-MBI) scan of the breast
Description: Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
Study NCT02067845 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Many Men, Many Voices (3MV) group level intervention
Description: The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning.
Study NCT02067845 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A group-based HIV/STI prevention intervention for women who have sex with women
Study NCT01763060 — intervention group
Intervention type: RADIATION
Intervention: CT scan
Study NCT01763060 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive function
Study NCT01763060 — intervention group
Intervention type: RADIATION
Intervention: MRI
Study NCT02235064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
Study NCT02235064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing cellulose powder of same color as experimental arm
Study NCT02194283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol - in single rising doses
Study NCT02194283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02844543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE-SYNC eye-tracking device
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
Study NCT02844543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCAT-3
Description: The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
Study NCT02844543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desktop Eye-Tracker
Description: Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
Study NCT01041157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Neck muscle trainings effect on botulinum toxin efficiency
Study NCT04082923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liquid meal
Description: Four-hour liquid mixed meal test
Study NCT04082923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solid meal
Description: Four-hour solid mixed meal test
Study NCT04262089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
Study NCT03563963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
Study NCT03563963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Preservative-Free Injectable Solution
Description: Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
Study NCT03563963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
Study NCT03881189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS® 200
Description: The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
Study NCT02501850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Treatment with liraglutide, exenatide or lixisenatide
Study NCT02501850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Treatment with metformin and/or sulphonilurea
Study NCT01991587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine